Previous Close | 0.0605 |
Open | 0.0610 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 0.0600 - 0.0610 |
52 Week Range | 0.0500 - 0.2010 |
Volume | |
Avg. Volume | 290,280 |
Market Cap | 19.393M |
Beta (5Y Monthly) | 1.46 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0700 |
Earnings Date | Jul 15, 2024 - Jul 19, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 0.25 |
Announced that its research site, Cedar Clinical Research, has been chosen as one of multiple sites ...
Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based novel therapies, is proud to announce that its research site, Cedar Clinical Research ("CCR"), has been chosen as one of multiple sites for Cybin's Phase 3 pivotal, multinational clinical trial of CYB003 for the adjunctive treatment of Major Depressive Disorder ("MDD").
Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, provides an update following unauthorized disclosure in an online newspaper which has come to its attention.